OncoMatch/Clinical Trials/NCT06090656
Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
Is NCT06090656 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Bevacizumab combined with Sintilimab for hepatocellular carcinoma.
Treatment: Bevacizumab combined with Sintilimab — Transcatheter arterial chemoembolization (TACE) is recommended as the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) (i.e., BCLC stage B). However, these patients is heterogeneous in terms of liver functional, tumor size and tumor number, and not all patients with mid-stage HCC will benefit from TACE. The ORIENT-32 trial confirmed the efficacy of sintilimab in combination with bevacizumab for unresectable hepatocellular carcinoma. No study has yet explored whether this regimen is appropriate for patients with BCLC stage B. The purpose of this study is to explore whether bevacizumab in combination with sintilimab is superior to conventional TACE therapy in patients with HCC with beyond-Up-to-seven criteria.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–0(Fully active)
Prior therapy
Cannot have received: systemic antitumor therapy
No systemic systemic antitumor therapy against hepatocellular carcinoma and transhepatic arterial intervention prior to treatment.
Cannot have received: transhepatic arterial intervention
No systemic systemic antitumor therapy against hepatocellular carcinoma and transhepatic arterial intervention prior to treatment.
Lab requirements
Blood counts
platelets >75×10E9/L; leukocytes >3.0×10E9/L; neutrophils >1.5×10E9/L
Kidney function
Serum creatinine less than 1.5 times the upper limit of normal (ULN)
Liver function
Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), transaminases ≤ 3 times the ULN, Child-Pugh A, no ascites, normal coagulation function, albumin ≥ 30g/L
Child-Push A Normal hematologic function (platelets >75×10E9/L; leukocytes >3.0×10E9/L; neutrophils >1.5×10E9/L) Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), transaminases ≤ 3 times the ULN No ascites, normal coagulation function, albumin ≥ 30g/L Serum creatinine less than 1.5 times the upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify